Received: 3 November 2021
Accepted: 15 February 2022
First Online: 24 February 2022
: This study was approved by Yale IRB.
: LP has received consulting fees from Pfizer, Bristol-Myers Squibb, AstraZeneca, Merck, Roche, Novartis, and Natera. MR has received funding from the ASCO YIA 2020 award. The rest of the authors do not have any competing interests to disclose.